Neuro-Oncology News

Researchers at Sylvester Comprehensive Cancer Center at University of Miami devised an MRI-guided radiation therapy technique using machine learning that may allow for real-time monitoring of glioblastoma treatment response.

A Boston-area biopharmaceutical has announced additional positive biomarker data from a phase 1/2a study of a novel cancer vaccine immunotherapeutic intended to treat those with recurrent glioblastoma.

An international team of investigators has identified a drug candidate that nearly doubles survival rates for patients with diffuse midline glioma, an aggressive type of childhood brain tumor.

Positive results from a pivotal phase 2b trial showed mirdametinib significantly improved the outcomes of patients with neurofibromatosis type 1-associated plexiform neurofibromas, SpringWorks Therapeutics announced in a press release.

A small-molecule chemotherapeutic did not improve efficacy compared with standard therapies in adults with glioblastoma, according to the manufacturer.

An implantable microdevice designed to test treatments in patients with gliomas during standard-of-care surgery has been easily and safely incorporated into surgical practice.

A novel oncolytic virus gene therapy extended survival among a small cohort of patients with high-grade glioblastoma, according to study results published in Nature.

A virtual reality therapy designed to ease anxiety associated with neuroimaging tests for patients with primary brain tumors appeared feasible, according to an interim analysis of a phase 2 clinical trial.

Today is Glioblastoma Awareness Day.

CHICAGO — Vorasidenib significantly improved PFS while delaying time to next intervention among certain patients with grade 2 isocitrate dehydrogenase 1- or 2-mutant glioma, according to data presented at ASCO Annual Meeting.